![conference banner](/images/conference-banner.jpeg)
Abstract
The prevention of excessive blood loss to avoid fatal haemorrhage is a pivotal process for all organisms possessing a circulatory system. Increased circulating blood volume and pressure, as required in larger animals, make this process all the more important and challenging. It is essential to have a powerful and rapid system to detect damage and generate an effective seal, and which is also exquisitely regulated to prevent unwanted, excessive or systemic activation so as to avoid blockage of vessels. Thus, a highly specialised and efficient haemostatic system has evolved that consists of cellular (platelets) and protein (coagulation factors) components. Importantly, this is able to support haemostasis in both the low shear environment of the venous system and the high shear environment of the arterial system. Endothelial cells, lining the entire circulation system, play a crucial role in the delicate balance between activation and inhibition of the haemostatic system. An intact and healthy endothelium supports blood flow by preventing attachment of cells and proteins which is required for initiation of coagulation and platelet activation. Endothelial cells produce and release the two powerful soluble inhibitors of platelet activation, nitric oxide and prostacyclin, and express high levels of CD39 which rapidly metabolises the major platelet feedback agonist, ADP. This antithrombotic environment however can rapidly change following activation or removal of endothelial cells through injury or rupture of atherosclerotic plaques. Loss of endothelial cells exposes the subendothelial extracellular matrix which creates strong signals for activation of the haemostatic system including powerful platelet adhesion and activation. Quantitative and qualitative changes in the composition of the subendothelial extracellular matrix influence these prothrombotic characteristics with life threatening thrombotic and bleeding complications, as illustrated by formation of atherosclerotic plaques or the disorder Ehler-Danlos syndrome, which is caused by a defect in collagen synthesis and is associated with fragile blood vessels. This review will focus on the role of the subendothelial matrix in haemostasis and thrombosis, highlighting its potential as a target for novel antithrombotics.
Current Pharmaceutical Design
Title: Platelet Activation by Extracellular Matrix Proteins in Haemostasis and Thrombosis
Volume: 15 Issue: 12
Author(s): Steve P. Watson
Affiliation:
Abstract: The prevention of excessive blood loss to avoid fatal haemorrhage is a pivotal process for all organisms possessing a circulatory system. Increased circulating blood volume and pressure, as required in larger animals, make this process all the more important and challenging. It is essential to have a powerful and rapid system to detect damage and generate an effective seal, and which is also exquisitely regulated to prevent unwanted, excessive or systemic activation so as to avoid blockage of vessels. Thus, a highly specialised and efficient haemostatic system has evolved that consists of cellular (platelets) and protein (coagulation factors) components. Importantly, this is able to support haemostasis in both the low shear environment of the venous system and the high shear environment of the arterial system. Endothelial cells, lining the entire circulation system, play a crucial role in the delicate balance between activation and inhibition of the haemostatic system. An intact and healthy endothelium supports blood flow by preventing attachment of cells and proteins which is required for initiation of coagulation and platelet activation. Endothelial cells produce and release the two powerful soluble inhibitors of platelet activation, nitric oxide and prostacyclin, and express high levels of CD39 which rapidly metabolises the major platelet feedback agonist, ADP. This antithrombotic environment however can rapidly change following activation or removal of endothelial cells through injury or rupture of atherosclerotic plaques. Loss of endothelial cells exposes the subendothelial extracellular matrix which creates strong signals for activation of the haemostatic system including powerful platelet adhesion and activation. Quantitative and qualitative changes in the composition of the subendothelial extracellular matrix influence these prothrombotic characteristics with life threatening thrombotic and bleeding complications, as illustrated by formation of atherosclerotic plaques or the disorder Ehler-Danlos syndrome, which is caused by a defect in collagen synthesis and is associated with fragile blood vessels. This review will focus on the role of the subendothelial matrix in haemostasis and thrombosis, highlighting its potential as a target for novel antithrombotics.
Export Options
About this article
Cite this article as:
Watson P. Steve, Platelet Activation by Extracellular Matrix Proteins in Haemostasis and Thrombosis, Current Pharmaceutical Design 2009; 15 (12) . https://dx.doi.org/10.2174/138161209787846702
DOI https://dx.doi.org/10.2174/138161209787846702 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PPARs and Diabetes-Associated Atherosclerosis
Current Pharmaceutical Design Pleiotropic Effects of HDL: Towards New Therapeutic Areas for HDL-Targeted Interventions
Current Molecular Medicine Transthyretin Deposition in Familial Amyloidotic Polyneuropathy
Current Medicinal Chemistry An Overview of the Effect of Weight Loss on Cardiovascular Autonomic Function
Current Diabetes Reviews Quantification of Low-Density and High-Density Lipoproteins in Human Serum by Material Enhanced Infrared Spectroscopy (MEIRS)
Current Medicinal Chemistry Oleic Acid in Olive Oil: From a Metabolic Framework Toward a Clinical Perspective
Current Pharmaceutical Design Editorial [Hot Topic:Role of Food and Nutritional Factors in Metabolic Syndrome X,Cancer and Cardiovascular Diseases (Guest Editor: Undurti N. Das)]
Current Nutrition & Food Science A Review of the Rational and Current Evidence on Colchicine for COVID-19
Current Pharmaceutical Design Protein Oxidation and Proteolytic Signalling in Aging
Current Pharmaceutical Design Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences
Current Pharmaceutical Biotechnology The Chemical Defensive System in the Pathobiology of Idiopathic Environment- Associated Diseases
Current Drug Metabolism Fetzima (levomilnacipran), a Drug for Major Depressive Disorder as a Dual Inhibitor for Human Serotonin Transporters and Beta-Site Amyloid Precursor Protein Cleaving Enzyme-1
CNS & Neurological Disorders - Drug Targets Immunomodulatory Effect of Probiotic Bacteria
Recent Patents on Inflammation & Allergy Drug Discovery Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Dyslipidemia as a Risk Factor for Ischemic Stroke
Current Topics in Medicinal Chemistry Does Angiotensin Converting Enzyme Inhibitor Protect the Heart in Cardiac Surgery? From Laboratory to Operating Room: Clinical Application of Experimental Study
Current Pharmaceutical Design Tangier Disease Four Decades of Research: A Reflection of the Importance of HDL
Current Medicinal Chemistry Peripheral Arterial Disease - The Forgotten Risk Factor
Vascular Disease Prevention (Discontinued) Knowledge of Complications of Diabetes Mellitus among Patients with Type 2 Diabetes in Saudi Arabia: A Descriptive Study
Current Diabetes Reviews Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy
Current Drug Targets